Axovant Gene Therapies (NASDAQ:AXGT) Stock Rating Upgraded by ValuEngine

Axovant Gene Therapies (NASDAQ:AXGT) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Thursday, ValuEngine reports.

A number of other research firms also recently weighed in on AXGT. Zacks Investment Research raised shares of Axovant Gene Therapies from a “hold” rating to a “strong-buy” rating and set a $5.50 price target on the stock in a research note on Friday, June 14th. JMP Securities increased their price target on shares of Axovant Gene Therapies from $8.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, June 6th. Evercore ISI started coverage on shares of Axovant Gene Therapies in a research note on Thursday, April 11th. They set an “outperform” rating on the stock. Svb Leerink started coverage on shares of Axovant Gene Therapies in a research note on Friday, June 21st. They set an “outperform” rating and a $18.00 price target on the stock. Finally, Leerink Swann started coverage on shares of Axovant Gene Therapies in a research note on Friday, June 21st. They set an “outperform” rating and a $5.79 price target on the stock. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Axovant Gene Therapies presently has an average rating of “Buy” and an average price target of $28.76.

NASDAQ:AXGT traded up $0.03 during trading hours on Thursday, reaching $6.97. 318,700 shares of the company were exchanged, compared to its average volume of 443,986. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 0.41. The stock has a market cap of $154.68 million, a price-to-earnings ratio of -0.87 and a beta of 1.28. Axovant Gene Therapies has a 52-week low of $3.81 and a 52-week high of $20.80. The company’s 50 day moving average is $6.51.

Axovant Gene Therapies (NASDAQ:AXGT) last posted its quarterly earnings results on Tuesday, June 11th. The company reported ($0.45) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.70) by $1.25. On average, analysts forecast that Axovant Gene Therapies will post -5.34 EPS for the current fiscal year.

In other Axovant Gene Therapies news, CEO Pavan Cheruvu bought 7,500 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were acquired at an average price of $5.21 per share, with a total value of $39,075.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 6.60% of the company’s stock.

Several hedge funds have recently modified their holdings of AXGT. Marshall Wace LLP purchased a new position in shares of Axovant Gene Therapies in the 1st quarter valued at $272,000. Primecap Management Co. CA purchased a new position in shares of Axovant Gene Therapies in the 1st quarter valued at $1,400,000. Finally, Sphera Funds Management LTD. purchased a new position in shares of Axovant Gene Therapies in the 1st quarter valued at $6,794,000.

Axovant Gene Therapies Company Profile

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Recommended Story: What is meant by buying and selling pressure?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Axovant Gene Therapies (NASDAQ:AXGT)

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.